Alan Nicholas
Impact in
- Hepatology top 1%
- Hepatocellular Carcinoma Treatment and Prognosis
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
Papers in
- Oncology 15
- Colorectal Cancer Treatments and Studies 8
- Cancer Treatment and Pharmacology 3
- Cancer Immunotherapy and Biomarkers 3
-
- Brain Metastases and Treatment 4
- Co-authors
- Richard S. Finn (6 shared papers)Ann‐Lii Cheng (6 shared papers)Peter R. Galle (6 shared papers)Philippe Merle (5 shared papers)Andrew X. Zhu (5 shared papers)Daneng Li (5 shared papers)Lindong Li (4 shared papers)Michel Ducreux (5 shared papers)
- Journals
- Journal of Clinical Oncology (12 papers)Liver Cancer (2 papers)Cancer Research (2 papers)Clinical Cancer Research (1 paper)The Oncologist (1 paper)
- Partner nations
- United StatesSwitzerlandGermany
In The Last Decade
Alan Nicholas
23 papers receiving 1.6k citations
Alan Nicholas's Hit Papers
Peers
Comparison fields: 5 of 73
- Hepatology 706
- Oncology 489
- Statistics and Probability 112
- Pulmonary and Respiratory Medicine 310
- Cancer Research 131
Countries citing papers authored by Alan Nicholas
This map shows the geographic impact of Alan Nicholas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan Nicholas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan Nicholas more than expected).
Fields of papers citing papers by Alan Nicholas
This network shows the impact of papers produced by Alan Nicholas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan Nicholas. The network helps show where Alan Nicholas may publish in the future.
Co-authors
The 25 scholars most cited alongside Alan Nicholas, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 23 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma Hit paper breakdown → | 2021 | 967 |
| 2 | 2017 | 138 | |
| 3 | 2019 | 107 | |
| 4 | 2021 | 70 | |
| 5 | 2018 | 50 | |
| 6 | 2021 | 40 | |
| 7 | 2018 | 40 | |
| 8 | 2021 | 28 | |
| 9 | 2020 | 20 | |
| 10 | 2022 | 19 | |
| 11 | 2024 | 16 | |
| 12 | 2021 | 14 | |
| 13 | 2021 | 12 | |
| 14 | 2017 | 11 | |
| 15 | 2023 | 10 | |
| 16 | 2022 | 9 | |
| 17 | 2020 | 7 | |
| 18 | 2023 | 5 | |
| 19 | 2017 | 5 | |
| 20 | 2022 | 3 |
About Alan Nicholas
Alan Nicholas is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Radiology, Nuclear Medicine and Imaging and Hepatology, having authored 23 papers that have together received 1.6k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (9 papers), Colorectal Cancer Treatments and Studies (8 papers), Hepatocellular Carcinoma Treatment and Prognosis (5 papers), Radiomics and Machine Learning in Medical Imaging (4 papers), Brain Metastases and Treatment (4 papers), Cancer Treatment and Pharmacology (3 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Bladder and Urothelial Cancer Treatments (2 papers). The work is most often cited by research in Hepatology (706 citations), Oncology (489 citations), Statistics and Probability (112 citations), Pulmonary and Respiratory Medicine (310 citations) and Cancer Research (131 citations). Alan Nicholas has collaborated with scholars based in United States, Switzerland and Germany. Frequent co-authors include Richard S. Finn, Ann‐Lii Cheng, Peter R. Galle, Philippe Merle, Andrew X. Zhu, Daneng Li, Lindong Li, Michel Ducreux, В. В. Бредер and Wendy Verret. Their work appears in journals such as Journal of Clinical Oncology, Liver Cancer, Cancer Research, Clinical Cancer Research and The Oncologist.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.